| Literature DB >> 25147602 |
Stefan Schunk1, Klaus Linz1, Sven Frormann1, Claudia Hinze1, Stefan Oberbörsch1, Bernd Sundermann1, Saskia Zemolka1, Werner Englberger1, Tieno Germann1, Thomas Christoph1, Babette-Y Kögel1, Wolfgang Schröder1, Stephanie Harlfinger1, Derek Saunders1, Achim Kless1, Hans Schick2, Helmut Sonnenschein2.
Abstract
We report the discovery of spiro[cyclohexane-pyrano[3,4-b]indole]-amines, as functional nociceptin/orphanin FQ peptide (NOP) and opioid receptor agonists with strong efficacy in preclinical models of acute and neuropathic pain. Utilizing 4-(dimethylamino)-4-phenylcyclo-hexanone 1 and tryptophol in an oxa-Pictet-Spengler reaction led to the formation of spiroether 2, representing a novel NOP and opioid peptide receptor agonistic chemotype. This finding initially stems from the systematic derivatization of 1, which resulted in alcohols 3-5, ethers 6 and 7, amines 8-10, 22-24, and 26-28, amides 11 and 25, and urea 12, many with low nanomolar binding affinities at the NOP and mu opioid peptide (MOP) receptors.Entities:
Keywords: MOP receptor agonist; NOP receptor agonist
Year: 2014 PMID: 25147602 PMCID: PMC4137372 DOI: 10.1021/ml500116x
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345